Roche Reports registry Data for Pembrolizumab in Ulcerative colitis

Roche today announced registry results for pembrolizumab in patients with ulcerative colitis. The study demonstrated that pembrolizumab reduces hospitalization rates compared to standard of care or placebo. These results provide important insights into the treatment of ulcerative colitis and support the continued development of pembrolizumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.